Boston Scientific Corp

Latest Results (22.10.2025):

Boston Scientific Corp reported strong financial results for the second quarter of 2025, achieving net sales of $5.061 billion, a 22.8% increase compared to the same period last year. The company also saw significant growth in net income and earnings per share, driven by robust performance across all business segments and geographic regions.

Net Sales Growth

In Q2 2025, Boston Scientific Corp achieved net sales of $5.061 billion, representing a 22.8% increase on a reported basis, 21.6% on an operational basis, and 17.4% on an organic basis compared to Q2 2024. These figures surpassed the company's guidance ranges of 17.5-19.5% reported growth and 13-15% organic growth.

Earnings Performance

The company reported a GAAP net income of $797 million, or $0.53 per share, up from $324 million or $0.22 per share in the previous year. Adjusted earnings per share (EPS) were $0.75, exceeding the projected range of $0.71 to $0.73 per share.

Segment and Regional Sales

Boston Scientific Corp experienced strong sales growth across all segments, with Cardiovascular leading at a 26.8% reported increase. Regionally, the United States saw a remarkable 30.7% growth in net sales, while Asia-Pacific and Emerging Markets also posted significant gains of 18.0% and 11.6%, respectively.

Product Approvals and Acquisitions

The company received FDA approval for the FARAPULSE™ Pulsed Field Ablation System and the CE mark for the WATCHMAN FLX™ Pro Left Atrial Appendage Closure Device. Additionally, Boston Scientific completed acquisitions of Intera Oncology Inc. and SoniVie Ltd., enhancing its portfolio in oncology and hypertension treatment technologies.

Future Guidance

Looking ahead, Boston Scientific Corp projects full-year 2025 net sales growth of approximately 18-19% on a reported basis and 14-15% on an organic basis. For the third quarter, the company anticipates net sales growth in the range of 17-19% reported and 12-14% organic, with EPS estimates also provided for continued strong financial performance.